AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$CATX

Lantheus Alpha Therapy, LLC sold $777K of CATX

Lantheus Alpha Therapy, LLC sold 247,932 shares of Perspective Therapeutics, Inc. (CATX) at an average of $3.13 ($3.11–$3.15, $0.78M total) across 2 trades over 2026-09-03 to 2026-09-04. Filed jointly with Lantheus Holdings, Inc. (10% owner).

Original reporting
SEC EDGAR · Lantheus Alpha Therapy, LLC, Lantheus Holdings, Inc.
Published Sep 8, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
high confidence
Mentioned
$CATX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The transaction represents a modest reduction in stake by a major owner, with limited immediate market effect.

02

Market read

Low relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data that prompted the sale.

Relevance 5/10Novelty 3/10Timing: filing today

Background

Form 4 filing by Lantheus Alpha Therapy, LLC reporting a sale of Perspective Therapeutics shares.

Company-level read

Ticker impact

$CATXNeutralHigh confidence
Context

SEC Form 4 disclosed a $777K open‑market sale of 247,932 shares by a 10% owner.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

Sale size is small relative to market cap and ownership remains high.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider may be reallocating capital; could signal confidence in future upside.

Key entities

  • company
    Perspective Therapeutics, Inc.

    Biopharma issuer of CATX.

  • entity
    Lantheus Alpha Therapy, LLC

    Reporting insider holder.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CATX insider trading history →

Related articles

OCT 8
$CATXMedAI 8/10

Perspective Granted FDA Fast Track for PSV359 in FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359, an investigational FAP-targeted alpha therapy, to treat adult patients with locally advanced or metastatic FAP-positive solitary fibrous tumors. The drug is currently in a Phase 1/2a study, with early human imaging showing promising results. Fast Track designation may expedite development and review processes.

tradingview.com1 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or…

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors SEATTLE, Oct. 08, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Co

SEC EDGAR 8-K2 min
OCT 8
$CATXMedAI 8/10

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

Perspective Therapeutics (CATX) received FDA Fast Track Designation for PSV359, a treatment for FAP-positive solitary fibrous tumors. The therapy targets FAP-α, a protein linked to aggressive cancers, with limited current treatment options. The FDA program aims to expedite development and review for serious conditions with unmet medical needs.

globenewswire.com2 min
OCT 7
$CATXLowAI 8/10

Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors

Perspective Therapeutics (NYSE: CATX) will present clinical data on its [212Pb]VMT-α-NET program for advanced neuroendocrine tumors at the NANETS 2026 symposium. The company is developing radiopharmaceutical treatments using alpha-emitting isotopes to target cancer cells. Interim data was previously presented at the 2026 ASCO meeting, with additional data planned for future conferences. The company is also advancing other clinical-stage programs in the U.S.

quiverquant.com1 min